BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 35720029)

  • 1. MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition.
    Gao C; Li J; Zeng F; Wang L; Chen K; Chen D; Hong J; Qu C
    Carcinogenesis; 2023 Jun; 44(4):279-290. PubMed ID: 37185675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minichromosome maintenance protein family member 6 mediates hepatocellular carcinoma progression by recruiting UBE3A to induce P53 ubiquitination.
    Zhang X; Bian S; Ni Y; Zhou L; Yang C; Zhang C; Sun X; Xu N; Xu S; Wang Y; Gu S; Zheng W
    Int J Biol Macromol; 2023 Sep; 248():125854. PubMed ID: 37460074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNF125‑mediated ubiquitination of MCM6 regulates the proliferation of human liver hepatocellular carcinoma cells.
    Feng X; Song D; Liu X; Liang Y; Jiang P; Wu S; Liu F
    Oncol Lett; 2024 Mar; 27(3):105. PubMed ID: 38298426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High MCM6 expression promotes proliferation and correlates with poor prognosis in triple-negative breast cancer.
    Zhang H; Lin YD; Zhuang MX; Zhu L; Yu Y; Chen XG; Wang QS; Lin MB
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2906-2922. PubMed ID: 38639528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer.
    Lei Z; Wang P; Jia DQ; Li LL; Wu YP; Yang Y; Pan GQ
    Front Biosci (Landmark Ed); 2023 Aug; 28(8):128. PubMed ID: 37664925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target.
    Wang Y; Chen H; Liu W; Yan H; Zhang Y; Cheung AHK; Zhang J; Chen B; Liang L; Zhou Z; Wong CC; Wu WKK; Chan MWY; Cheng ASL; Ma BBY; Yu J; Lo KW; To KF; Kang W
    Theranostics; 2022; 12(15):6509-6526. PubMed ID: 36185598
    [No Abstract]   [Full Text] [Related]  

  • 7. Signaling pathways in liver cancer: pathogenesis and targeted therapy.
    Xue Y; Ruan Y; Wang Y; Xiao P; Xu J
    Mol Biomed; 2024 May; 5(1):20. PubMed ID: 38816668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retracted:
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9845039. PubMed ID: 37475947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA replication: Mechanisms and therapeutic interventions for diseases.
    Song HY; Shen R; Mahasin H; Guo YN; Wang DG
    MedComm (2020); 2023 Feb; 4(1):e210. PubMed ID: 36776764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
    Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
    BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA replication regulator MCM6: An emerging cancer biomarker and target.
    Zeng T; Guan Y; Li YK; Wu Q; Tang XJ; Zeng X; Ling H; Zou J
    Clin Chim Acta; 2021 Jun; 517():92-98. PubMed ID: 33609557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer.
    Zheng Y; Shi Y; Yu S; Han Y; Kang K; Xu H; Gu H; Sang X; Chen Y; Wang J
    Anal Cell Pathol (Amst); 2019; 2019():1038069. PubMed ID: 32082966
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Hou L; Zeng X; Li X; Zhao C; Zou J; Li Y; Liu G
    Comput Math Methods Med; 2022; 2022():3116303. PubMed ID: 35720029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
    Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
    J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of MCM6 on hepatocellular carcinoma in a Southern Chinese Zhuang population.
    Jia W; Xie L; Wang X; Zhang Q; Wei B; Li H; Qin S; Chen S; Liu J; Tan Y; Zheng S; Liang X; Yang X
    Biomed Pharmacother; 2020 Jul; 127():110171. PubMed ID: 32403044
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.